Caladrius Biosciences (NASDAQ:CLBS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Wednesday. They presently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 106.90% from the company’s current price.
Separately, Zacks Investment Research lowered Caladrius Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th.
Shares of Caladrius Biosciences (CLBS) opened at $5.80 on Wednesday. Caladrius Biosciences has a one year low of $2.63 and a one year high of $7.79. The stock has a market capitalization of $54.46, a P/E ratio of 2.75 and a beta of 1.46.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.